retatrutide 2025 trial results Phase 3: 60% Achieved Surgical-Level Weight Loss Eli Lilly's Phase 3 data

She believes patients deserve longer visits, individualized treatment plans, and access to the most current evidence-based therapies not just what fits the standard 15-minute appointment

The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving

If your goal is sustained weight management without injections, this daily oral option can offer meaningful benefitsbut only when taken correctly

Dexfenfluramine and pergolide cause heart valve disease via valve metabolic reprogramming and ongoing matrix remodeling

We don't know yet